GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Denosumab - PROLIA subcutaneous injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Denosumab - PROLIA subcutaneous injection

Product / population
PROLIA for its labeled bone indications; not an XGEVA or biosimilar dosing substitution.
Renal method
Indexed eGFR <30 mL/min/1.73 m2; dialysis/CKD-MBD population retained
Source revision
6/2026
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

PROLIA: no adjustment does not mean routine-risk treatment

Both retrieved sources contain advanced-CKD hypocalcemia precautions. This is not a disagreement or a missing-warning claim. Dose unchanged and CKD-MBD safety assessment are different questions.

What to reconcile: Complete the advanced-CKD assessment and monitoring plan with appropriate expertise; do not substitute the nonadvanced-CKD monitoring interval.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

No renal dose adjustment does not remove advanced-CKD safeguards

Selected mirror and June 2026 label paragraphs agree. Advanced-CKD calcium surveillance differs from the nonadvanced-CKD 10-14-day instruction.

What to reconcile: Review CKD-MBD and the advanced-CKD monitoring plan before using the no-adjustment statement.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

Denosumab - PROLIA subcutaneous injection

Open original reference

DailyMed / Amgen Inc. · PROLIA for its labeled bone indications; not an XGEVA or biosimilar dosing substitution.

Renal method: Indexed eGFR <30 mL/min/1.73 m2; dialysis/CKD-MBD population retained
Source date: 6/2026
Retrieved: 2026-09-10

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Use the advanced-CKD monitoring schedule, not the separate nonadvanced-CKD 10-14-day instruction.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In advanced CKD (eGFR <30 mL/min/1.73 m2), including dialysis, evaluate CKD-MBD before treatment using iPTH, calcium, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D; consider bone-turnover assessment. Correct pre-existing hypocalcemia. Monitor calcium weekly for the first month after a dose and monthly thereafter, with adequate calcium and activated vitamin D and CKD-MBD-experienced supervision. Calcimimetics can add risk. The separate 10-14-day monitoring advice for predisposed patients without advanced CKD is not this advanced-CKD schedule. No renal dose adjustment does not remove these safeguards.

RDM60-official-denosumab-prolia-027fc85709-C1 · Source locator: 2.2; 5.1; 8.6

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88
Retrieved
2026-09-10
Exact label title
Denosumab - PROLIA subcutaneous injection
DailyMed Set ID
49e5afe9-a0c7-40c4-af9f-f287a80c5c88
Labeler
Amgen Inc.
DailyMed page updated
2026-06-26
Label revision
6/2026
Renal-function method
Indexed eGFR <30 mL/min/1.73 m2; dialysis/CKD-MBD population retained
Source date/version
6/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
11f7cf7806d6a7911f6603bff59eae09a6767cf95b6c26e0e1dd8179c79314c5

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=denosumab-prolia&s1=RDM60-official-denosumab-prolia-027fc85709&h1=a9c661a0ee2687a6f8eeb44e01c6e4bf0381550ea196a89cb1dabc56abd3f9cd